Anaferon tablets, No. 20

Anaferon is indicated for use in adults.

-treatment and prevention of influenza and ARVI as part of complex therapy;

-complex treatment of newly diagnosed and recurrent labial and genital herpes.

The drug is taken orally, not during meals. The tablet should be kept in the mouth until it is completely dissolved. The risk is not intended for dividing the tablet into parts.

SARS, flu, labial herpes

On the 1st day, take 8 tablets. according to the following scheme: 1 tab. every 30 minutes in the first 2 hours (only 5 tab. for 2 hours), then during the same day, take another 1 tab. 3 times at regular intervals. On the 2nd day and then take 1 tab. 3 times / day until complete recovery.

If there is no improvement on the 3rd day of treatment with ARVI and influenza, you should consult a doctor.

In the epidemic season of acute respiratory viral infections and influenza, for prophylactic purposes, the drug is taken daily 1 time / day for 1-3 months.

Genital herpes

In case of acute manifestations of genital herpes, the drug is taken at regular intervals according to the following scheme: 1-3 days - 1 tab. 8 times / day, then - 1 tab. 4 times / day for at least 3 weeks.

For the prevention of recurrences of chronic herpesvirus infection - 1 tablet / day. The recommended duration of the prophylactic course is determined individually and can be up to 6 months.

If necessary, the drug can be combined with other antiviral and symptomatic agents.

Lozenges from white to almost white, flat-cylindrical shape, with a score and a bevel; the flat side with scribbles has the inscription MATERIA MEDICA, the other flat side has the inscription ANAFERON.

1 tab.

antibodies to human gamma interferon affinity purified 0.003 g *

* applied to lactose monohydrate in the form of a water-alcohol mixture with a content of not more than 10-15 ng / g of the active form of the active substance.

Excipients: lactose monohydrate - 0.267 g, microcrystalline cellulose - 0.03 g, magnesium stearate - 0.003 g.

• Age under 18;

• lactase deficiency, lactose intolerance, glucose-galactose malabsorption;

• increased individual sensitivity to the components of the drug.

pharmachologic effect

With prophylactic and therapeutic use, the drug has an immunomodulatory and antiviral effect. Efficiency against influenza viruses and herpes simplex viruses of types 1 and 2 (labial herpes, genital herpes) has been experimentally and clinically established. The drug reduces the concentration of the virus in the affected tissues, affects the system of endogenous interferons and associated cytokines, induces the formation of endogenous 'early' interferons (IFN? /?) And interferon gamma (IFN?).

Stimulates the humoral and cellular immune response. Increases the production of antibodies (including secretory IgA), activates the functions of T-effectors, T-helpers (Tx), normalizes their ratio. Increases the functional reserve of Th and other cells involved in the immune response. It is an inducer of a mixed Tx1- and Th2-type immune response: it increases the production of cytokines Th1 (IFN?, IL-2) and Th2 (IL-4, 10), normalizes (modulates) the balance of Th1 / Th2 activities. Increases the functional activity of phagocytes and natural killer cells (NK cells).

Pharmacokinetics

The sensitivity of modern physicochemical methods of analysis (gas-liquid chromatography, high-performance liquid chromatography, gas chromatography-mass spectrometry) does not allow assessing the content of the active components of Anaferon in biological fluids, organs and tissues, which makes it technically impossible to study pharmacokinetics.

Side effect

Allergic reactions and manifestations of increased individual sensitivity to the components of the drug are possible.

Application during pregnancy and lactation

The safety of using Anaferon during pregnancy and lactation has not been studied. If necessary, taking the drug should take into account the benefit / risk ratio.

Application in children

The use of the drug under the age of 18 is contraindicated.

special instructions

The drug contains lactose monohydrate, and therefore it is not recommended to prescribe it to patients with congenital galactosemia, glucose malabsorption syndrome or congenital lactase deficiency.

Overdose

Overdose cases have not been registered so far. In case of an accidental overdose, dyspeptic symptoms are possible due to the fillers included in the drug.

Drug interactions

To date, no cases of incompatibility with other drugs have been identified.

If necessary, the drug can be combined with other antiviral, antibacterial and symptomatic agents.